1. EFFECT OF MELATONIN OVER SLEEP QUALITY IN OLDER ADULTS WITH MILD TO MODERATE DEMENTIA
- Author
-
Camara Lemarroy C, Morales R, Gamez Treviño D, Arredondo Jaime A, Hernandez Maldonado E, Salinas Martinez R, and Guajardo Álvarez G
- Subjects
Pediatrics ,medicine.medical_specialty ,Health (social science) ,Sleep quality ,business.industry ,Health Professions (miscellaneous) ,Melatonin ,Abstracts ,Text mining ,Moderate dementia ,Medicine ,Life-span and Life-course Studies ,business ,medicine.drug - Abstract
Background: Sleep disturbances are common in patients with dementia. Melatonin treatment is purported to improve sleep, and benefit those patients. Methods: Randomized, placebo-controlled, double blind clinical trial. Older adults with mild to moderate dementia with poor sleep quality were included and randomized to receive melatonin (5 mg, by mouth, once daily) or placebo for 8 weeks. PSQI was assessed at baseline and every 2 weeks. Mini mental state examination (MMSE), Katz and Lawton Brody score were assessed at baseline and last visit. Numerical variables were compared using student T test and repeated measures ANOVA; and Chi square test for categorical variables. (IBM SPSS version 17.0). Results: 22 patients were included, 12 in Melatonin Group (MG) and 10 of placebo group (PG). There were no statistical differences for gender (MG: 58% and PG: 50% females) and mean age of 82.4 ± 6 (MG) and 84.9 ± 2 (PG). There was no statistical difference between groups at baseline: GDS, MMSE, evolution of dementia, comorbidities or medication use and PSQI (MG:13.4 ± 3.1 and PG:13.3 ± 3.8, p=0.9). In melatonin group, there was a statistical significant decrease from baseline and all subsequent evaluations, reaching 6.8 ± 3.6 (a reduction of 6.6 points) at week 8 (p=0.01). There was no statistical difference of PSQI for placebo group through the study (9.4 ± 5.4 at week 8, p=0.4). Conclusions: We found a significant improvement in PSQI scores in melatonin group and no adverse events were reported. Treatment with Melatonin is safe, tolerable and effective in improving quality of sleep in older people with dementia.
- Published
- 2017